VANCOUVER, British Columbia, May 13, 2024 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (the “Company or Cannabix”) has entered into an arm's length marketing agreement with the following parties: is reported.
Effective May 13, 2024, we entered into a 30-day fee agreement of $10,000 with Financial Buzz Media Networks LLC (“FBMN”). We may renew the agreement at any time during the term. The Services include, but are not limited to, video news summaries and press release editorial syndication covering the latest news releases. The consideration paid to FBMN does not include securities of the Company, 3 Columbus Circle 15th Floor, New York, 877-601-1879.
The Company has entered into an agreement with aktiencheck.de AG (“aktiencheck”) for a period of 30 days from May 2, 2024 for a fee of EUR 20,000. We may choose to extend the Agreement at any time during the Term. Services include, but are not limited to, editorial writing, translation, search engine marketing, native advertising, and email marketing. The consideration paid to aktiencheck does not include securities of the Company (address: Bahnhofstr. 6, 56470 Bad Marienberg, Germany, info@aktiencheck.de).
The Company has contracted with InvestorsHub.com Inc. (“InvestorsHub”) for news release distribution services from May 7, 2024 until funds are exhausted, for a fee of $4,800. We may choose to renew the Agreement in the future. The consideration paid to InvestorsHub does not include any securities of the Company (address: PO Box 780, Harrisonville, MO 6470, 888-498-5839).
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol breathalyzer technology for law enforcement, workplaces, and laboratories. Cannabix develops delta-9 THC and alcohol screening devices. Delta-9 THC is the psychoactive component of marijuana that causes impairment. Breath testing for delta-9 THC allows employers and law enforcement to identify recent cannabis use. Cannabix is the developer of his Breath Logix series of breath alcohol detection devices for employers and a variety of other settings.
We want a safe harbor.
on behalf of the board of directors
“Love Mullite”
CEO
Cannabis Technologies Co., Ltd.
Please contact us for more information. info@cannabixtechnologies.com
CSE has not reviewed and is not responsible for the adequacy or accuracy of this release.
Cautionary note regarding forward-looking statements
This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information may include, without limitation, statements that are based on current expectations that involve a number of risks and uncertainties, including, but not limited to, the final development of commercial or prototype products, and the success of clinical trials and pilots; This does not guarantee our future performance. There can be no assurance that commercial sales of any kind will actually materialize for the Company's technology. There can be no assurance that we will have sufficient funds to complete product development. There are a number of risks and uncertainties that could cause actual results and our plans and objectives to differ materially from those expressed in forward-looking information. (ii) risks related to the protection of proprietary technology; (iii) our ability to complete financing; (iv) our ability to develop and market future products; (v) risks related to government regulation, managing and sustaining growth, the effects of adverse publicity, litigation, competition and other factors identified from time to time in our public announcements and filings; There can be no assurance that the development of breathalyzer technology will be profitable to us, nor can there be any assurance that any proposed new products will be developed and successfully completed in beta testing or clinical trials. There can be no assurance that our breathalyzer technology evaluators will enter into any type of sales contract or enter into any agreements or agreements regarding sales. There can be no assurance that existing “patent pending” technology licensed by us will receive patent status with regulatory authorities. We do not currently sell commercial breathalyzers. Actual results and future events may differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on management's estimates and opinions as of the date on which they are made and are expressly qualified in their entirety by this communication. We do not intend to update these forward-looking statements except as required by law.
